Emcure Pharma Receives CDSCO Approval for Poviztra to Treat Liver Disease
Emcure Pharmaceuticals has received approval from India's Central Drugs Standard Control Organisation (CDSCO) to market Poviztra, its co-marketed brand of innovator semaglutide, for treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. Poviztra, manufactured by Novo Nordisk in Europe, is the first GLP-1 receptor agonist approved in India for this progressive liver disease linked to obesity and diabetes. The approval is supported by Phase III ESSENCE trial results showing significant improvements in liver inflammation and fibrosis. Emcure aims to increase awareness and access to this treatment for patients with this often underdiagnosed condition.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 44/100.
Outlets measured: news18, economictimes, thetribune, thefinancialexpress, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 20 Jul, 11:48 am. Other outlets followed.